[{"id":"5d9e65c6-b900-41df-834e-6e18a16cdf9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470203","created_at":"2026-03-28T01:44:18.552Z","updated_at":"2026-03-28T01:44:18.552Z","phase":"","brief_title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT07470203","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/31/2026","start_date":" 03/31/2026","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"06f9902f-3398-49ea-bdd4-ce2518db4d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886531","created_at":"2021-05-14T12:52:33.790Z","updated_at":"2025-02-25T13:49:09.000Z","phase":"Phase 2","brief_title":"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","source_id_and_acronym":"NCT04886531","lead_sponsor":"Ruth O'Regan","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-21"},{"id":"ae6dde76-a9e2-4ffe-85b4-d60ff795f82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03919292","created_at":"2021-01-18T19:17:11.532Z","updated_at":"2025-02-25T13:48:40.499Z","phase":"Phase 1/2","brief_title":"Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca","source_id_and_acronym":"NCT03919292","lead_sponsor":"Virginia Commonwealth University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • RAS mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-21"},{"id":"1a0f9386-4e8b-4cdd-9e39-8af1012d0af9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05215548","created_at":"2022-02-05T18:27:48.529Z","updated_at":"2025-02-25T14:08:36.534Z","phase":"Phase 2","brief_title":"Primary Tumor Resection With EGFR TKI for Stage IV NSCLC","source_id_and_acronym":"NCT05215548","lead_sponsor":"National Taiwan University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-19"},{"id":"8edf0eb7-d0e0-49b2-b787-cd7e18808b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT02597946","created_at":"2021-01-18T12:36:41.049Z","updated_at":"2025-02-25T14:00:49.865Z","phase":"Phase 2","brief_title":"Afatinib in NSCLC With HER2 Mutation","source_id_and_acronym":"NCT02597946","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • KIT","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2 • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 07/22/2018","primary_completion_date":" 07/22/2018","study_txt":" Completion: 07/22/2018","study_completion_date":" 07/22/2018","last_update_posted":"2025-02-19"},{"id":"a00222c5-3654-4b1c-8e1f-3f6063d2350d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03083678","created_at":"2021-01-18T15:11:26.156Z","updated_at":"2025-02-25T15:10:32.768Z","phase":"Phase 2","brief_title":"Afatinib in Locally Advanced and Metastatic Chordoma","source_id_and_acronym":"NCT03083678","lead_sponsor":"Leiden University Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-13"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"830f0798-1d87-4b27-be23-d2bdac97c17f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01649271","created_at":"2021-01-18T07:06:15.291Z","updated_at":"2025-02-25T15:25:12.158Z","phase":"Phase 1","brief_title":"Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.","source_id_and_acronym":"NCT01649271","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/23/2012","start_date":" 07/23/2012","primary_txt":" Primary completion: 06/23/2016","primary_completion_date":" 06/23/2016","study_txt":" Completion: 06/23/2016","study_completion_date":" 06/23/2016","last_update_posted":"2025-02-11"},{"id":"0061b93e-583a-42c0-8bd3-4e877410955f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00950742","created_at":"2021-01-18T03:41:51.942Z","updated_at":"2025-02-25T15:25:03.808Z","phase":"Phase 1","brief_title":"Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.","source_id_and_acronym":"NCT00950742","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 10/01/2013","study_completion_date":" 10/01/2013","last_update_posted":"2025-02-10"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"4e07ea78-21b2-4abe-9c7a-53c1c0d6fed9","acronym":"KAN-HER2 MRD","url":"https://clinicaltrials.gov/study/NCT05388149","created_at":"2022-05-24T12:54:32.375Z","updated_at":"2025-02-25T17:25:36.146Z","phase":"Phase 2","brief_title":"Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease","source_id_and_acronym":"NCT05388149 - KAN-HER2 MRD","lead_sponsor":"University Health Network, Toronto","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/06/2022","start_date":" 12/06/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-01-31"},{"id":"257cca5a-c910-4b83-b699-e799dee41eab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101748","created_at":"2021-01-18T15:16:53.226Z","updated_at":"2025-02-25T13:52:17.471Z","phase":"Phase 1/2","brief_title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03101748","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • daunorubicin • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 01/29/2018","start_date":" 01/29/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-13"},{"id":"002e6ccc-3a81-4cfa-b237-64f0c73db083","acronym":"INTUITT-NF2","url":"https://clinicaltrials.gov/study/NCT04374305","created_at":"2021-01-18T21:07:59.980Z","updated_at":"2025-02-25T14:51:47.217Z","phase":"Phase 2","brief_title":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","source_id_and_acronym":"NCT04374305 - INTUITT-NF2","lead_sponsor":"Scott R. Plotkin, MD, PhD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"2b8e2f91-c4ad-4a30-bf4b-d41f2c7c9a84","acronym":"INSIGhT","url":"https://clinicaltrials.gov/study/NCT02977780","created_at":"2021-01-18T14:38:25.857Z","updated_at":"2025-02-25T14:36:55.862Z","phase":"Phase 2","brief_title":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","source_id_and_acronym":"NCT02977780 - INSIGhT","lead_sponsor":"Patrick Wen, MD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-10-17"},{"id":"6f4faf68-b16d-468b-9596-4d2ec114a446","acronym":"","url":"https://clinicaltrials.gov/study/NCT02364609","created_at":"2021-01-18T11:15:31.840Z","updated_at":"2025-02-25T16:14:29.149Z","phase":"Phase 1","brief_title":"Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib","source_id_and_acronym":"NCT02364609","lead_sponsor":"Jonathan Riess","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • erlotinib • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2024-10-16"},{"id":"8d1ccb5b-f750-498e-b8e0-01cc46ef60cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919108","created_at":"2023-06-26T14:09:19.440Z","updated_at":"2024-07-02T16:34:26.575Z","phase":"Phase 2","brief_title":"Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers","source_id_and_acronym":"NCT05919108","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • CDH1","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 04/30/2030","primary_completion_date":" 04/30/2030","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2024-06-13"},{"id":"5281d885-db71-4720-b9bf-1c0b248f2e5b","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372614","created_at":"2022-05-13T12:54:23.489Z","updated_at":"2024-07-02T16:34:58.772Z","phase":"Phase 1","brief_title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","source_id_and_acronym":"NCT05372614 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD4 • CASP3","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA","tags":["HER-2 • CD4 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 06/17/2024","study_completion_date":" 06/17/2024","last_update_posted":"2024-06-05"},{"id":"8b6df141-7b64-4f9b-89f3-9e3e39a78d70","acronym":"NCI-2017-00831","url":"https://clinicaltrials.gov/study/NCT03066206","created_at":"2021-01-17T17:10:50.278Z","updated_at":"2024-07-02T16:35:01.092Z","phase":"Phase 2","brief_title":"Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC","source_id_and_acronym":"NCT03066206 - NCI-2017-00831","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"12d6f8bf-b8cc-4e05-aaf9-f067a1855bd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01494662","created_at":"2021-01-18T06:15:41.454Z","updated_at":"2024-07-02T16:35:02.079Z","phase":"Phase 2","brief_title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","source_id_and_acronym":"NCT01494662","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine) • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-22"},{"id":"8c54ec0b-d0c1-4fe6-a519-4d78f4e6dc25","acronym":"","url":"https://clinicaltrials.gov/study/NCT04909073","created_at":"2021-06-01T17:53:35.882Z","updated_at":"2024-07-02T16:35:02.774Z","phase":"","brief_title":"Observational Study of Afatinib 30 mg Daily","source_id_and_acronym":"NCT04909073","lead_sponsor":"National University Hospital, Singapore","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-17"},{"id":"9c382546-d526-411a-9404-d92947184867","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085755","created_at":"2023-10-17T15:12:33.857Z","updated_at":"2024-07-02T16:35:03.809Z","phase":"Phase 1/2","brief_title":"Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer","source_id_and_acronym":"NCT06085755","lead_sponsor":"Jeeyun Lee","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-14"},{"id":"3a04215f-16bc-463d-a8c7-22a54bd276e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06109467","created_at":"2023-10-31T18:13:37.416Z","updated_at":"2024-07-02T16:35:06.096Z","phase":"Phase 2","brief_title":"Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer","source_id_and_acronym":"NCT06109467","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • Nerlynx (neratinib) • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/12/2024","start_date":" 01/12/2024","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-05-03"},{"id":"5cbd364b-f758-45a6-86eb-66a9228fce4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06302621","created_at":"2024-03-13T01:30:21.478Z","updated_at":"2024-07-02T16:35:07.278Z","phase":"Phase 1","brief_title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT06302621","lead_sponsor":"Massachusetts General Hospital","biomarkers":" FGFR2","pipe":"","alterations":" ","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-26"},{"id":"b04da804-4c66-4d69-84c9-7b541be7c700","acronym":"","url":"https://clinicaltrials.gov/study/NCT03377387","created_at":"2021-01-18T16:40:04.269Z","updated_at":"2024-07-02T16:35:09.006Z","phase":"Phase 1/2","brief_title":"Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer","source_id_and_acronym":"NCT03377387","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-18"}]